We are live on ! Find out more
FLNA

Filana Therapeutics

153 hedge funds and large institutions have $326M invested in Filana Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 45 increasing their positions, 39 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

51% more capital invested

Capital invested by funds: $215M → $326M (+$110M)

44% more call options, than puts

Call options by funds: $81.5M | Put options by funds: $56.7M

15% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 39

9% more funds holding

Funds holding: 140153 (+13)

3.49% more ownership

Funds ownership: 30.83%34.32% (+3.5%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
153
Holders Change
+13
Holders Change %
+9.29%
% of All Funds
2.23%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
31
Increased
45
Reduced
39
Closed
16
Calls
$81.5M
Puts
$56.7M
Net Calls
+$24.8M
Net Calls Change
+$18.3M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$68.4M +$4.19M +198,431 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$52.3M +$1.18M +56,060 +2%
Morgan Stanley
3
Morgan Stanley
New York
$24.4M +$13.7M +649,305 +150%
State Street
4
State Street
Massachusetts
$24.1M +$931K +44,059 +4%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$19.7M +$924K +43,746 +5%
GCM
6
Gallacher Capital Management
Colorado
$13.1M +$79.9K +3,782 +0.7%
CAC
7
Cowen and Company
New York
$11.3M +$10.6M +500,000 New
Northern Trust
8
Northern Trust
Illinois
$8.73M +$296K +14,032 +4%
Jane Street
9
Jane Street
New York
$8.42M +$7.62M +360,686 +2,668%
Charles Schwab
10
Charles Schwab
California
$6.95M +$86.9K +4,115 +1%
N
11
Nuveen
North Carolina
$6.27M +$1.85M +87,663 +46%
National Bank of Canada
12
National Bank of Canada
Quebec, Canada
$5.93M +$3.13M +148,000 +127%
Bank of America
13
Bank of America
North Carolina
$5.27M -$8.19M -387,862 -62%
Norges Bank
14
Norges Bank
Norway
$4.87M
Goldman Sachs
15
Goldman Sachs
New York
$3.64M +$2.29M +108,456 +204%
CCFM
16
Clear Creek Financial Management
Washington
$3.03M +$639K +30,265 +29%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$2.98M -$56.7K -2,686 -2%
Osaic Holdings
18
Osaic Holdings
Arizona
$2.66M -$220K -10,400 -8%
SPS
19
Susquehanna Portfolio Strategies
Pennsylvania
$2.49M +$2.33M +110,412 New
Barclays
20
Barclays
United Kingdom
$2.38M +$1.67M +78,888 +295%
JFG
21
Jefferies Financial Group
New York
$2.2M -$2.95M -139,463 -59%
SG Americas Securities
22
SG Americas Securities
New York
$2.08M -$3.89M -184,073 -67%
UBS Group
23
UBS Group
Switzerland
$1.89M +$1.19M +56,170 +203%
Swiss National Bank
24
Swiss National Bank
Switzerland
$1.77M -$182K -8,600 -10%
Invesco
25
Invesco
Georgia
$1.7M +$1.24M +58,679 +349%

FLNA Hedge Fund Activity: Q4 2023 in Review

153 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2023, worth a combined $326M — up 51% from $215M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new FLNA positions and 16 closed out — a net gain of 15 holders — while 45 added to existing stakes and 39 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $13.7M. The largest seller was Bank of America, cutting an estimated $8.19M.

  • 153 institutional investors held Filana Therapeutics (FLNA) as of Q4 2023, up from 140 in Q3 2023.
  • Funds reported $326M of Filana Therapeutics stock for Q4 2023, up 51% quarter-over-quarter.
  • 31 funds opened new Filana Therapeutics positions in Q4 2023 and 16 closed out, a net change of +15 holders.
  • The largest Filana Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $13.7M added.
  • The largest Filana Therapeutics seller in Q4 2023 was Bank of America, an estimated $8.19M sold.

Based on aggregated 13F filings for Q4 2023.